Introduction {#s001}
============

S[chizophrenia and other]{.smallcaps} psychoses often present in childhood and adolescence with consequent impairments in psychosocial functioning and quality of life. Early-onset psychosis (EOP, age of onset before 18 years) is considered a more severe disorder than adult-onset psychosis and is accompanied by a higher level of negative and nonspecific symptoms (García et al. [@B8]). Patients with EOP have a poor prognosis, severe depressive symptoms, and a high death rate (Ropcke and Eggers [@B29]; Remschmidt et al. [@B27]). More safe and effective treatments are needed for these vulnerable youths.

Antipsychotic medication is the mainstay for the clinical treatment of mental diseases and functions differently in youths and adults. Weight gain and metabolic disturbances are more likely to occur in children and adolescents than in adults who take antipsychotic drugs (Arango et al. [@B2]; Baeza et al. [@B3]). The use of antipsychotics in children and adolescents has been controversial. In Europe and the United States, the clinical trials are expensive. Many ethical restrictions and no clear financial incentive to perform pediatric efficacy or safety trials support have resulted in a lack of relevant clinical trials. In the United States, only five new antipsychotics (i.e., aripiprazole, olanzapine, paliperidone, quetiapine, and risperidone) have been approved by the American Food and Drug Administration for the treatment of schizophrenia in children and adolescents. Second-generation antipsychotics (SGAs) are preferred over first-generation antipsychotics for the treatment of children and adolescents due to their typical lower rates of extrapyramidal symptoms (EPS) and tardive dyskinesia (Correll et al. [@B6]; Correll and Kane [@B5]). Previous knowledge regarding SGAs was largely obtained from studies involving adults with psychosis. Clinical trials, particularly active-controlled trials involving children and adolescents with psychosis, have been limited, and their sample sizes have been small. It turns out that active-control trials with large samples in pediatric patients do exist, but they are usually industry sponsored or drug companies tend not to publish unless their drug does better.

Olanzapine and risperidone, which are the two most commonly used SGAs, play important roles in the treatment of children and adolescents with psychosis. A systematic review and meta-analysis (Kumar et al. [@B19]) of studies obtained from the Cochrane Library compared olanzapine with risperidone in youth, but included only 2 randomized controlled trials (RCTs) with merely 111 participants. Furthermore, few RCTs have been included in other relevant reviews or meta-analyses (Seida et al. [@B30]; Harvey et al. [@B10]), and all have been obtained from English-language databases. According to a 5-year survey (Yan and Cui [@B34]), olanzapine has been used most frequently (24.6%) in China to treat children and adolescents with schizophrenia, followed by risperidone (21.9%). Thus, we conducted this meta-analysis of RCTs obtained from both English and Chinese language databases to compare the efficacy and safety of olanzapine and risperidone for the treatment of children and adolescents with psychosis.

Methods {#s002}
=======

Search strategy and selection criteria {#s003}
--------------------------------------

We systematically searched English (i.e., PubMed, Embase, and the Cochrane Library) and Chinese (i.e., VIP service platform, Chinese Biomedical Literature Service System \[CBM\], Chinese National Knowledge Infrastructure \[CNKI\], and WANFANG DATA) databases for RCTs that compared the efficacy and safety of olanzapine and risperidone in the treatment of children and adolescents with psychosis and were published before February 8, 2017 using the following terms and combinations of Chinese equivalent words: "olanzapine" AND "risperidone" AND ("children" OR "adolescent") AND ("schizophrenia" OR "psychosis" OR "schizophrenia spectrum and other psychotic disorders"). To avoid omissions, we inspected the references of all identified studies to identify additional relevant studies.

According to the principle of PICOS in evidence-based medicine, studies were included if they met the following criteria: Participants: all subjects aged ≤18 years with a diagnosis of a schizophrenia spectrum or other psychotic disorder; Intervention and Comparison: olanzapine and risperidone; Outcomes: efficacy and safety; and Study design: only RCTs. The following studies and articles were excluded: observational studies, retrospective studies, animal studies, reviews, and duplicate articles.

Data extraction and outcome measures {#s004}
------------------------------------

Potentially relevant studies were screened using Endnote X6 by two independent investigators (L.X. and W.-Z.L.) according to the prespecified criteria. The following data were extracted from the studies: authors, year of publication, group status (types and doses of antipsychotics and sample size), duration, blind evaluation, age of subjects, diagnoses, and outcome measures. Any disagreements were addressed by a discussion between the two investigators to reach a consensus. Otherwise, a third senior investigator (H.-Z.L.) was involved in the discussion as a final arbiter.

The main outcome measure of efficacy was the total score on the Positive and Negative Syndrome Scale (PANSS) (Kay et al. [@B18]) or the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham [@B25]). The secondary outcomes were the scores on the positive and negative symptom subscale of the PANSS or the Children\'s Psychiatric Rating Scale (CPRS) (Fish [@B7]). The main outcome measures of side effects included changes in weight and body mass index (BMI) and the incidence of various adverse events.

Quality assessment {#s005}
------------------

The quality of each study was assessed using the Cochrane Risk of Bias (ROB) tool (Higgins and Julian [@B11]), including seven specific aspects, and the Jadad scale (Jadad et al. [@B16]) (high quality ≥3 and low quality \<3). The quality of the overall evidence was assessed using the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) (Guyatt et al. [@B9]). The overall level of each outcome was marked as "high," "moderate," "low," or "very low."

Data synthesis and statistical analysis {#s006}
---------------------------------------

Different effect measures were chosen and analyzed using Review Manager Version 5.3 software according to the data type. We obtained the 95% confidence intervals (CIs) and drew forest maps to perform the data analysis. The mean difference (MD) was calculated for continuous data acquired using the same methods (e.g., weight and BMI). The standard MD (SMD) was calculated for continuous data acquired using different methods (e.g., scores of different scales). Risk ratios (RRs) with the 95% Cl were calculated for dichotomous data (e.g., incidence of adverse events). Statistical differences were considered significant at *p* \< 0.05.

The study heterogeneity was estimated using I^2^ and chi-square test of homogeneity (Higgins et al. [@B12]). If *p* \> 0.10 and i^2^ \< 50%, which indicated homogeneity, a fixed-effect model was used. If *p* ≤ 0.10 or 50%≤I^2^ ≤ 75%, which indicated significant heterogeneity, a random-effect model was used. If I^2^ \> 75%, we either conducted an exclusive sensitivity analysis or abandoned the meta-analysis.

Results {#s007}
=======

Study characteristics {#s008}
---------------------

The search initially identified 1649 potentially relevant studies. After removing duplicate records and screening according to the prespecified criteria, eight RCTs (Sikich et al. [@B32], [@B31]; Huang et al. [@B13]; Mozes et al. [@B24]; Wei [@B33]; Liu and Yan [@B20]; Jiang and Gu [@B17]; Qi et al. [@B26]) were ultimately included ([Fig. 1](#f1){ref-type="fig"}). Three articles (Sikich et al. [@B32], [@B31]; Mozes et al. [@B24]) were published in English and five articles (Huang et al. [@B13]; Wei [@B33]; Liu and Yan [@B20]; Jiang and Gu [@B17]; Qi et al. [@B26]) in Chinese. Since we systematically searched four main Chinese databases, five out of the eight studies meeting our screening criteria were from the Chinese-language literature.

![Flowchart of study selection.](fig-1){#f1}

[Table 1](#T1){ref-type="table"} lists the eight RCTs, which involved 457 participants (sample size range, 25--80 patients). The mean trial duration was 8.5 weeks (range, 8--12 weeks). Six studies included two groups, that is, olanzapine *versus* risperidone, and two studies included three groups. Among these studies, five studies were conducted in China (*n* = 321), two studies in the United States (*n* = 111), and one study in Israel (*n* = 25). Different scales were used to assess efficacy and safety in these studies.

###### 

[Study Characteristics]{.smallcaps}

                                                                                          *Diagnosis*                                                                                                                               
  ------------------------ ------------- -------------- -------------- ---- ---- -------- ----------------------------------------- ---------------------------------------- -------- ---------------------- ---------------------- -----------
  Sikich et al. ([@B32])   OLA           12.3 ± 4.5     14.6 ± 3.1     16   8    DB       K-SADS                                    5 (31)^[a](#tf1){ref-type="table-fn"}^   BPRS-C   AIMS                   14 (88)                3 (18.8)
  RIS                      3.3 ± 1.5     14.6 ± 2.9     19                       SCID     13 (68)^[a](#tf1){ref-type="table-fn"}^   CRPS                                     SAS      14 (74)                11 (57.9)              
  HAL                                                                                                                               CGI                                                                                             
  Huang et al. ([@B13])    OLA           7.8 ± 3. 4     14.1 ± 1.7     34   8    OL       CCMD-3                                    34 (100)                                 BPRS     TESS                   21 (61.8), 29 (85.3)   1 (2.9)
  RIS                      3.5 ± 1.6     13.7 ± 2.1     32                                32 (100)                                                                                    17 (53.1), 25 (78.1)   3 (9.4)                
  Mozes et al. ([@B24])    OLA           8.18 ± 4.41    11.5 ± 1.64    12   12   OL       K-SADS                                    6 (50)                                   PANSS    SAS                    5 (41.7), 8 (66.7)     1 (8.3)
  RIS                      1.62 ± 1.02   10.71 ± 1.43   13                       DSM-IV   9 (69)                                    BPRS                                     BAS      4 (30.8), 6 (46.2)     4 (30.7)               
  Sikich et al. ([@B31])   OLA           11.4 ± 5.0     8--19          35   8    DB       DSM-IV                                    22 (63)                                  PANSS    SAS                    12 (34)                18 (51.4)
  RIS                      2.8 ± 1.4                    41                  BA            28 (68)                                   BPRS-C                                   BAS      19 (46)                                       
  MOL                                                                                                                               CGI                                      AIMS                            13 (31.7)              
  Wei ([@B33])             OLA           10--20         15.1 ± 1.7     28   8    OL       CCMD-3                                    28 (100)                                 BPRS     TESS                   16 (57.1), 25 (89.3)   0 (0)
  RIS                      2--6          14.8 ± 1.9     27                                27 (100)                                                                                    15 (55.6), 22 (81.5)   1 (3.6)                
  Liu and Yan ([@B20])     OLA           ≤ 20           13.6 ± 3.2     30   8    NA       CCMD-3                                    30 (100)                                 PANSS    TESS                   24 (80), 28 (93.3)     NA
  RIS                      ≤ 5           11.4 ± 2.9     30                                30 (100)                                                                                    24 (80), 27 (90.0)                            
  Qi et al. ([@B26])       OLA           11.8 ± 2.9     7--16          40   8    BA       CCMD-3                                    40 (100)                                 PANSS    TESS                   21 (52.5), 35 (87.5)   NA
  RIS                      3.4 ± 1.1                    40                                40 (100)                                                                                    24 (60.0), 36 (90.0)                          
  Jiang and Gu ([@B17])    OLA           ≤ 15           10\. 1 ± 4.2   30   8    NA       NA                                        30 (100)                                 BPRS     TESS                   14 (46.7), 28 (93.3)   NA
  RIS                      ≤ 4           9\. 5 ± 4.1    30                                30 (100)                                  PANSS                                             12 (40.0), 26 (86.7)                          

The study only reported the number of patients with schizophrenia spectrum disorders.

NA, no information available; OLZ, olanzapine; RIS, risperidone; HAL, haloperidol; MOL, molindone; SCH, schizophrenia; DB, double blind; OL, open label; BA, blind assessor; AIMS, Abnormal Involuntary Movement Scale; BAS, Barnes Akathisia Rating Scale; BPRS, the Brief Psychiatric Rating Scale; BPRS-C, the Brief Psychiatric Rating Scale for Children total score; CCMD-3, 3rd edition of Chinese Classification of Mental Disorders; CGI, Clinical Global Impression; CRPS, the Children\'s Psychiatric Rating Scale; DSM-IV, 4th edition of Diagnostic and Statistical Manual of Mental Disorder; K-SADS, Kiddies Schedule for Affective Disorders and Schizophrenia; PANSS, Positive and Negative Syndrome Scale; SAS, Simpson-Angus scale; SCID, the Structured Clinical Interview for DSM-IV; TESS, Treatment Emergent Symptoms Scale.

The rates of clinical response in the groups per study are shown in [Table 1](#T1){ref-type="table"}. Five studies (Sikich et al. [@B32], [@B31]; Huang et al. [@B13]; Mozes et al. [@B24]; Wei [@B33]) reported the rates and reasons of dropouts in details. The criteria used to determine clinical response varied across studies: CGI-I of "1" or "2" and reduction in the BPRS-C total score ≥20% (Sikich et al. [@B32]); CGI-I of "1" or "2" and reduction in the PANSS total score ≥20% (Sikich et al. [@B31]); reduction in the PANSS total score ≥50% and ≥30%, respectively (Mozes et al. [@B24]); reduction in the BPRS total score ≥75% and ≥30%, respectively (Jiang and Gu [@B17]); reduction in the PANSS total score ≥50% and ≥25%, respectively (Liu and Yan [@B20]); and four grades of response assessments---cure, excellence, improvement, and failure (Huang et al. [@B13]; Wei [@B33]; Qi et al. [@B26]). When necessary, two formulae were used to calculate the rates of clinical response: $$\documentclass{aastex}\usepackage{amsbsy}\usepackage{amsfonts}\usepackage{amssymb}\usepackage{bm}\usepackage{mathrsfs}\usepackage{pifont}\usepackage{stmaryrd}\usepackage{textcomp}\usepackage{portland, xspace}\usepackage{amsmath, amsxtra}\usepackage{upgreek}\pagestyle{empty}\DeclareMathSizes{10}{9}{7}{6}\begin{document}
\begin{align*}
& {\rm{Rat}}{{ \rm{e}}_{{ \rm{excellence}}}} \; = \; ( {{
\rm{N}}_{{ \rm{cure}}}} \; + \;{{ \rm{N}}_{{ \rm{excellence}}}} )
/ {{ \rm{N}}_{{ \rm{total}}}} \; \times \;100 \% ; \\ & {
\rm{Rat}}{{ \rm{e}}_{{ \rm{improvent}}}} \; = \; \left( {{{
\rm{N}}_{{ \rm{cure}}}} \; + \;{{ \rm{N}}_{{ \rm{excellence}}}} \;
+ { \rm{ \;}}{{ \rm{N}}_{{ \rm{improvent}}}}} \right) / {{
\rm{N}}_{{ \rm{total}}}} \; \times \;100 \%.
\end{align*}
\end{document}$$

ROB and Jadad score {#s009}
-------------------

The ROB in each study was assessed based on seven items ([Table 2](#T2){ref-type="table"}). Most items were considered "unclear risk" because of the lack of specific details regarding the research methods used in the studies. Only one RCT reported the method of allocation concealment, specifically stating that the medications were packaged in identical color-coded capsules, and two RCTs described a reasonable generation of a random sequence. In three non-Chinese RCTs, many participants dropped out (Discontinuation: *n* ≥ 20%), and an intent-to-treat analysis was used for incomplete outcome data. Of these eight RCTs, two RCTs were double blind, three RCTs were open label, and two RCTs used a blind assessor. The mean Jadad score of the eight RCTs was 2.9 (range, 1--6) and the high-quality RCTs accounted for 37.5% (3/8 RCTs).

###### 

[Risk of Bias and Jadad Scores]{.smallcaps}

  *Study*                  *Random sequence generation*   *Allocation concealment*   *Blinding of participants and personnel*   *Blinding of outcome assessment*   *Incomplete outcome data*   *Selective reporting*   *Other biases*   *Jadad score*
  ------------------------ ------------------------------ -------------------------- ------------------------------------------ ---------------------------------- --------------------------- ----------------------- ---------------- ---------------
  Sikich et al. ([@B32])   L                              NA                         L                                          NA                                 H                           NA                      NA               5
  Huang et al. ([@B13])    NA                             NA                         H                                          NA                                 L                           NA                      NA               2
  Mozes et al. ([@B24])    NA                             NA                         H                                          NA                                 H                           NA                      NA               2
  Sikich et al. ([@B31])   NA                             L                          L                                          L                                  H                           L                       NA               6
  Wei ([@B33])             NA                             NA                         H                                          NA                                 L                           NA                      NA               2
  Liu and Yan ([@B20])     L                              NA                         NA                                         NA                                 NA                          NA                      NA               3
  Qi et al. ([@B26])       NA                             NA                         NA                                         L                                  NA                          NA                      NA               2
  Jiang and Gu ([@B17])    NA                             NA                         NA                                         NA                                 NA                          NA                      NA               1

NA, no information available; L, low risk; H, high risk.

Efficacy {#s010}
--------

Since the outcome measure of efficacy was assessed using different scales (PANSS: three RCTs; BPRS: three RCTs; and both: two RCTs), the SMD was used in the meta-analysis. The I^2^-value was acceptable. However, the corresponding *p*-value was too small (I^2^ = 38%, *p* = 0.05). Hence, we used a random-effect model. The results of the meta-analysis showed no significant differences in the total scores on the PANSS or BPRS between the two groups (SMD = −0.06, 95% CI = \[−0.31, 0.19\], *p* = 0.63) ([Fig. 2](#f2){ref-type="fig"}). Furthermore, a sensitivity analysis was performed after excluding Wei\'s study as an outlier. The I^2^ value was reduced to 5% (I^2^ = 5%, *p* = 0.39) and there was still no statistical difference in total score between olanzapine and risperidone groups (SMD = −0.13, 95% CI = \[−0.33, 0.06\], *p* = 0.19).

![Forest plot used to compare the total scores on the Positive and Negative Syndrome Scale or Brief Psychiatric Rating Scale between the olanzapine and risperidone groups in children and adolescents with psychosis. SD, standard deviation; CI, confidence interval.](fig-2){#f2}

The positive and negative symptom scores of the 276 patients in 5 RCTs (Sikich et al. [@B32], [@B31]; Mozes et al. [@B24]; Liu and Yan [@B20]; Qi et al. [@B26]) were compared using the SMD (CPRS: 1 RCTs and PANSS: 4 RCTs). [Figure 3](#f3){ref-type="fig"} presents the homogeneity in both the positive (*p* = 0.72, I2 = 0%) and negative (*p* = 0.66, I2 = 0%) symptom scores. Therefore, a fixed-effect model was used. No significant difference was observed in either the positive symptom score (SMD = −0.09, 95% CI = \[−0.32, 0.15\], *p* = 0.48) or the negative symptom score (SMD = −0.11, 95% CI = \[−0.34, 0.13\], *p* = 0.38) between the two groups. According to the criteria of the GRADE approach, the quality of the evidence of the outcome measures of the total, positive, and negative symptom scores was rated as "moderate."

![Forest plot used to compare the subscale scores between the olanzapine and risperidone groups in children and adolescents with psychosis. SD, standard deviation; CI, confidence interval.](fig-3){#f3}

Adverse side effects {#s011}
--------------------

The adverse side effects were reported in all eight RCTs ([Table 1](#T1){ref-type="table"}), five (Huang et al. [@B13]; Wei [@B33]; Liu and Yan [@B20]; Jiang and Gu [@B17]; Qi et al. [@B26]) of which used the Treatment Emergent Symptoms Scale (TESS) (Zhang [@B35]). The changes in weight (MD = 2.90, 95% CI = \[1.41, 4.39\], *p* = 0.0001, kg) and BMI (MD = 0.90, 95% CI = \[0.42, 1.38\], *p* = 0.0003, kg/m^2^) were significantly higher in the olanzapine group than those in the risperidone group ([Table 3](#T3){ref-type="table"}). The quality of the evidence was rated as "moderate" according to the GRADE criteria.

###### 

[Comparisons of Weight Changes and Body Mass Index Changes Between the Olanzapine and Risperidone Groups]{.smallcaps}

  *Index (change)*   *No. of studies*   *Sample size*   *I*^2^           p      *Analytic model*   *Mean difference \[95% CI\]*
  ------------------ ------------------ --------------- ---------------- ------ ------------------ ------------------------------
  Weight             4                  211             62%              0.05   Random             **2.90 \[1.41, 4.39\]**
  BMI                2                  111             0%               1.00   Fixed              **0.90 \[0.42, 1.38\]**
  Cholesterol        1                  34              Not applicable   ---    Fixed              30.10 \[12.57, 47.63\]
  Triglycerides      1                  33              Not applicable   ---    Fixed              14.50 \[−25.10, 54.10\]
  Prolactin          1                  76              Not applicable   ---    Fixed              −21.00 \[−30.39, −11.61\]
  QTc                1                  76              Not applicable   ---    Fixed              −10.70 \[0.09, 21.31\]

Statistical differences are bold.

BMI, body mass index; QTc, QTc interval; CI, confidence interval.

[Table 4](#T4){ref-type="table"} displays a comparison of the incidence of 33 different adverse events between the olanzapine and risperidone groups. The RR is shown for each item, and a fixed-effect model was used. The incidence of hypersomnia/sedation (RR = 1.98, 95% CI = \[1.15, 3.43\], *p* = 0.01) was higher in the olanzapine group, while the incidence of insomnia (RR = 0.31, 95% CI = \[0.11, 0.85\], *p* = 0.02), prolactin elevation (RR = 0.11, 95% CI = \[0.01, 0.85\], *p* = 0.03), myotonia (RR = 0.12, 95% CI = \[0.03, 0.49\], *p* = 0.003), tremor (RR = 0.22, 95% CI = \[0.08, 0.63\], *p* = 0.005), or akathisia (RR = 0.27, 95% CI = \[0.12, 0.57\], *p* = 0.0007) was higher in the risperidone group. The quality of this evidence was rated as "low."

###### 

[Comparison of the Incidence of 33 Different Adverse Events Between the Olanzapine and Risperidone Groups]{.smallcaps}

  *Adverse event (incidence)*                        *No. of studies*   *Sample size*   *I*^2^*, %*   p       *Analytic model*   *Risk ratio \[95% CI\]*
  -------------------------------------------------- ------------------ --------------- ------------- ------- ------------------ -------------------------
  Excitement or agitation                            2                  135             0             0.83    fixed              0.25 \[0.03, 2.15\]
  Hypersomnia                                        5                  276             0             0.71    fixed              **1.98 \[1.15, 3.43\]**
  Insomnia                                           4                  255             0             0.89    fixed              **0.31 \[0.11, 0.85\]**
  Abnormal liver function/enzymes                    3                  201             41            0.03    fixed              1.71 \[0.66, 4.42\]
  Prolactin increase                                 2                  120             0             0.04    fixed              **0.11 \[0.01, 0.85\]**
  Granulopenia                                       1                  55              ---           ---     not applicable     0.19 \[0.01, 3.85\]
  Myotonia                                           4                  255             0             0.82    fixed              **0.12 \[0.03, 0.49\]**
  Tremors                                            4                  255             0             0.67    fixed              **0.22 \[0.08, 0.63\]**
  Torsional motion                                   1                  80              ---           ---     not applicable     0.14 \[0.01, 2.68\]
  Akathisia                                          5                  280             37            0.17    fixed              **0.27 \[0.12, 0.57\]**
  EPS                                                2                  91              89            0.003   not applicable     0.38 \[0.04, 3.74\]
  Dry mouth                                          4                  221             0             0.42    fixed              1.24 \[0.53, 2.91\]
  Blurred vision                                     4                  241             0             0.67    fixed              0.55 \[0.19, 1.66\]
  Constipation                                       4                  210             0             0.76    fixed              1.74 \[0.55, 5.50\]
  Increased salivation                               2                  115             0             0.56    fixed              0.30 \[0.05, 1.76\]
  Nausea                                             1                  35              ---           ---     not applicable     0.17 \[0.01, 3.03\]
  Sudation                                           1                  80              ---           ---     not applicable     0.50 \[0.05, 5.30\]
  Dizziness                                          4                  236             0             0.49    fixed              1.41 \[0.45, 4.41\]
  Sychnosphygmia                                     3                  201             31            0.23    fixed              0.67 \[0.21, 2.17\]
  Arrhythmia                                         2                  120             20            0.26    fixed              0.71 \[0.15, 3.50\]
  Abnormal T-wave                                    1                  55              ---           ---     not applicable     3.12 \[0.30, 32.03\]
  Skin symptom                                       2                  90              0             0.95    fixed              0.18 \[0.02, 1.43\]
  Weight gain                                        4                  255             4             0.37    fixed              1.37 \[0.65, 2.91\]
  Anorexia                                           1                  55              ---           ---     not applicable     0.32 \[0.01, 7.57\]
  Headache                                           3                  155             0             0.90    fixed              0.79 \[0.27, 2.30\]
  Abnormal electroencephalogram,                     1                  55              ---           ---     not applicable     0.96 \[0.06, 14.65\]
  urinary retention                                  1                  35              ---           ---     not applicable     3.53 \[0.15, 81.11\]
  Nervousness                                        1                  35              ---           ---     not applicable     2.38 \[0.24, 23.84\]
  Dysuria                                            1                  35              ---           ---     not applicable     3.53 \[0.15, 81.11\]
  Weakness                                           1                  35              ---           ---     not applicable     1.19 \[0.08, 17.51\]
  Irregular menses^[a](#tf7){ref-type="table-fn"}^   1                  13              ---           ---     not applicable     0.86 \[0.07, 10.96\]
  Musculoskeletal Pain                               1                  35              ---           ---     not applicable     2.38 \[0.50, 11.32\]
  Decreased coordination                             1                  35              ---           ---     not applicable     3.53 \[0.15, 81.11\]

Statistical differences are bold.

The sample size of this item included the number of females only.

EPS, extrapyramidal symptoms.

Discussion {#s012}
==========

Main findings {#s013}
-------------

This meta-analysis of 8 RCTs involving 457 participants found no significant differences in the mean score on the PANSS/BPRS or in the positive or negative symptom scores between the olanzapine and risperidone groups. Based on the GRADE criteria, the quality of this evidence was "moderate." Altogether, there is no difference in efficacy between olanzapine and risperidone for the treatment of children and adolescents with psychosis. However, it is worthy of mention that it is hard to interpret the study results without evaluating the "adequacy" of the included trials. From the literature, we did not know whether they all reached therapeutic doses (chlorpromazine equivalent) and sustained these therapeutic doses for sufficient duration, and whether those doses were maximal efficacy (which can exceed 30 mg for olanzapine). Thus, this conclusion that risperidone and olanzapine are equivalent in efficacy may be statistically accurate; however, [Figure 2](#f2){ref-type="fig"} suggests a clear trend toward olanzapine superiority for total PANSS and BPRS scores. Taken together, whether the clinical efficacy of olanzapine for the treatment of children and adolescents with psychosis is equivalent or superior to risperidone will need to be confirmed in the new and large sample size of clinical trials in future investigation before a firm conclusion could be drawn.

Regarding the adverse side effects, the changes in weight and BMI were significantly higher in the olanzapine group than in the risperidone group. These results are consistent with those reported in a previous meta-analysis of 14 RCTs, which showed that olanzapine was associated with the greatest weight increase, aripiprazole with the lowest weight increase, and risperidone in between (Almandil et al. [@B1]). In addition, there were significant differences in the incidence of hypersomnia/sedation, insomnia, prolactin elevation, myotonia, tremor, and akathisia between the two groups. In summary, olanzapine has a greater impact on body weight and BMI, while risperidone displays more side effects in the areas of myotonia, tremor, akathisia, and other EPS.

Olanzapine and risperidone, which are similar to other SGAs, exert their antipsychotic effect by blocking dopamine D~2~ and serotonin 5-HT~2A~ receptors (Mauri et al. [@B22]). Certain pharmacological mechanisms can explain the similarity in their efficacy and the difference in their side effects (Buckley [@B4]). First, targeted dopaminergic blockade occurs in different locations within the brain. EPS result from dopamine antagonism in the forebrain basal nuclei, and elevated prolactin results from the inhibition of the D~2~ receptor in the anterior pituitary gonadotropic cells. Second, D~2~ receptor occupancy can predict different reactions to the drugs, such as a clinical response (≥65%), elevated prolactin (∼72%), and EPS (\>78%). Although SGAs achieve the level of binding required for efficacy, only some SGAs, such as risperidone and not olanzapine, achieve the high level of binding that results in side effects. In addition, olanzapine has a strong binding affinity to histamine H~1~ and muscarinic acetylcholine M receptors. Thus, olanzapine has a considerable sedative effect (Miller [@B23]). Its anticholinergic activity may be an additional factor that explains the low incidence of EPS (Hyde and Crook [@B14]). The mechanism of weight gain induced by SGAs has not been identified to date, but is likely associated with activity that occurs at several different receptors (i.e., H~1~, 5-HT~2A~, 5-HT~2C~, M~3~, and adrenergic receptors). Currently, more attention is focused on the H~1~ receptor (Roerig et al. [@B28]). Due to the widespread interpersonal variation in the sensitivity to antipsychotics, there are no drugs or fixed doses that can achieve a clinical response without any side effects. Further studies that specifically target the pediatric population are needed. Moreover, the rates of response for both SGAs are generally \<50% in children and adolescents, with some side effects. Thus, we should individualize the drug choice and dosage regimen for the treatment of these pediatric patients. However, it is noteworthy that the D~2~ receptor occupancy argument for efficacy and adverse effects is complicated. The presence of EPS and neuroleptic malignant syndrome with antipsychotics is prima facie evidence that all of them are capable of occupying sufficient D~2~ receptors to induce side effects. Disparate results have been generated based on species (humans, monkeys, and rats), imaging modality (PET vs. SPECT), and dosing. Functional features such as intrinsic efficacy likely play a substantial role in efficacy and adverse effects, independent of receptor occupancy (Iyo et al. [@B15]; Marazziti et al. [@B21]).

Limitations {#s014}
-----------

There are several limitations to our study. First, few RCTs evaluating the use of SGAs in children or adolescents were found, and most studies involving adults were removed during the screening process. The use of antipsychotics in the pediatric population remains controversial, and conditions are difficult to control in clinical trials. Second, the overall quality of the studies included was low. Most studies did not provide specific details about their research methods. In particular, in the Chinese RCTs, the generation of a random sequence and allocation concealment were questionable. In addition, many participants dropped out in the non-Chinese RCTs, which may be related to this clinical situation in which Chinese patients are hospitalized for a longer period of time than others. Third, we could not collect data regarding the effects of therapeutic doses and treatment duration due to inadequate information. Finally, children and adolescents with psychosis need a full-course therapy, and we cannot assess the medium and long-term prognoses based on trials that lasted only a few weeks. These limitations reduce the credibility of our conclusions.

Clinical Significance {#s015}
=====================

The results of this meta-analysis indicate that olanzapine and risperidone are not significantly different in their efficacy in the treatment of children and adolescents with psychosis, but the side effect profiles of the two medications differ. These findings have implications for the selection of antipsychotic drugs in clinical practice. However, this is a preliminary study with several limitations. Also, selecting more reasonable treatment plans according to the patients\' specific situations and designing more rational studies with larger sample sizes, particularly involving children and adolescents, are necessary.
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